-
Mashup Score: 3Single cell analysis in AML - 3 year(s) ago
Measurable residual disease (MRD) is a readout used to inform prognosis and treatment decisions in patients with acute myeloid leukemia (AML), and there are currently two main techniques available to evaluate MRD.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0What can we learn from studying familial AML? - 3 year(s) ago
Interview with Courtney DiNardo, MD Anderson Cancer Center, Houston, US about the familial AML
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎞️ Watch our interview with Courtney DiNardo from #SOHO2020 where we asked: What can we learn from studying familial AML? https://t.co/KMFWOvEi4F #leusm https://t.co/qMrvkSRRZO
-
-
Mashup Score: 1The spectrum of clonal hematopoiesis - 3 year(s) ago
Clonal hematopoiesis (CH) describes the growth of a sub-population of blood cells that have at least one somatic mutation, leading to a greater risk of hematological malignancy and cardiovascular disease, and an increased risk of mortality from non-hematological malignancies.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In case you missed it ✅ The spectrum of clonal hematopoiesis: a summary of @DrKTakahashi, @MDAndersonNews’s Meet the Professor presentation during the #SOHO2020 meeting ➡️ https://t.co/XjeJxOvKLL #leusm https://t.co/AHWOwhEZKP
-
-
Mashup Score: 0Lymphodepletion optimization for CAR T-cell therapy - 3 year(s) ago
Chimeric antigen receptor (CAR) T-cell therapy is becoming more common in the treatment of both hematological and solid tumors. Prior to infusion, lymphodepletion is frequently performed, however, no standardized protocol exists for this procedure.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Is lymphodepletion prior to CAR T-cell therapy necessary? We know that Cy/Flu is the most used lymphodepletion regimen, but how can it be improved? https://t.co/DNlz17Pkpq #CARTcells #mmsm #myeloma #SOHO2020 @elizabeth_budde https://t.co/wJz4YymOo9
-
-
Mashup Score: 0Why high-dose therapy plus auto-SCT still plays a role in newly diagnosed multiple myeloma - 3 year(s) ago
High-dose therapy (HDT), often coupled with autologous stem cell transplantation (auto-SCT), has been a mainstay of treatment for newly diagnosed patients with multiple myeloma (MM).
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Is HDT followed by auto-SCT still relevant for treating MM, or have new treatments replaced it? Read the overview by @AjayNookaMD at #SOHO2020. https://t.co/fOBCvJXTz8 #mmsm https://t.co/MSIvq5mfR3
-
-
Mashup Score: 2Single cell analysis in AML - 3 year(s) ago
Measurable residual disease (MRD) is a readout used to inform prognosis and treatment decisions in patients with acute myeloid leukemia (AML), and there are currently two main techniques available to evaluate MRD.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Can single-cell analysis help understand resistance and response to AML therapies? At #SOHO2020, @pvyas_oxford outlined the progress being made regarding single-cell MRD analysis in AML. Read more on the @AML_Hub ➡️ https://t.co/IitXnDr8Am #leusm https://t.co/OWICeGvBJr
-
-
Mashup Score: 3Targeting p53 in MDS - 3 year(s) ago
David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses p53 mutations in the context of patients with myelodysplastic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @VJHemOnc: VIDEO: Targeting p53 in #MDS w/ David Sallman of @MoffittNews: https://t.co/RiOqGhdWAN @SocietyofHemOnc #SOHO2020 #HemOnc #M…
-
-
Mashup Score: 1Current treatment landscape for relapsed MCL - 3 year(s) ago
Jonathon B. Cohen, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA, provides an overview of the current treatment…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Current treatment landscape for relapsed #MCL with @jonathonbcohen of @EmoryMedicin: https://t.co/jZBL6IKqr4 @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #Lymsm #Lymphoma #MantleCellLymphoma #CART #CaxTx
-
-
Mashup Score: 0ZUMA-1: outcomes of CAR-T in older patients - 3 year(s) ago
Sattva S Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the outcomes of a post-hoc…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: ZUMA-1: outcomes of #CART cell therapy in older patients with Sattva Neelapu of @MDAndersonNews: https://t.co/W5vB742fvo @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #CTSM #TrialUpdate #ImmunoOnc #CaxTx
-
-
Mashup Score: 0Immuno-oncology approaches in MDS - 3 year(s) ago
Naval Daver, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, explores the use of immuno-oncology in…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Immuno-oncology approaches in #MDS with @Daver_Leukemia of @LeukemiaMDA: https://t.co/iabu0KkBeK @SocietyofHemOnc #SOHO2020 #OncoAlert @OncoAlert #MDSsm #ImmunoOnc #CaxTx
-
⏰ In case you missed it! Can single-cell analysis help understand resistance and response to AML therapies? At #SOHO2020, @pvyas_oxford outlined the progress being made regarding single-cell MRD analysis in AML. 👉 https://t.co/nvNt3I1sqI 👈 #leusm #amlsm #leukemia